Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study

Publikation: Bidrag til tidsskriftLetterForskningpeer review

DOI

  1. Prediction of Excessive Weight Gain in Insulin Treated Patients with Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Striated muscle fiber size, composition, and capillary density in diabetes in relation to neuropathy and muscle strength

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Glucagon Receptor Signaling and Glucagon Resistance

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jakob S Knudsen
  • Reimar W Thomsen
  • Anton Pottegård
  • Filip K Knop
  • Henrik T Sørensen
Vis graf over relationer

Highlights This population-based real-world prescription study characterized all new users of liraglutide in northern Denmark from 2009 to 2015. More than half (57%) the patients had liraglutide prescribed as part of drug combinations outside the originally approved indications. Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73% of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1-5 trials that led to liraglutide registration, underscoring the need for further post-marketing studies.

OriginalsprogEngelsk
TidsskriftJournal of Diabetes
Vol/bind11
Udgave nummer8
Sider (fra-til)690-694
Antal sider5
ISSN1753-0393
DOI
StatusUdgivet - aug. 2019

    Forskningsområder

  • cross-sectional studies, diabetes pharmacology, drug utilization, glucagon-like peptide-1 receptor, liraglutide

ID: 57062355